AcelRx Pharmaceuticals, Inc. (ACRX)
ACRXPrice: $0.86
Fair Value: 🔒
🔒score
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. ... more
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and com... more
Description
Shares
| Market Cap | $14.58M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Vincent J. Angotti |
| IPO Date | 2011-02-11 | CAGR | — |
| Employees | 19 | Website | www.acelrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.17% | Total Yield | -0.17% |
ACRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $25.05M | P/E Ratio | -0.31 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 942.24 | P/B Ratio | 6.46 |
| P/CF Ratio | -3.69 | P/FCF Ratio | -2.19 |
| EPS | $-2.75 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -186.18% | Gross Margin | 48.74% |
| Operating Margin | -494.59% | Profit Margin | -418.7% |
| ROE | -1.51% | ROA | -0.68% |
| ROCE | -0.96% | Current Ratio | 2.93 |
| Quick Ratio | 2.93 | Cash Ratio | 2.58 |
| Debt/Equity | 0.98 | Interest Coverage | — |
| Altman Z Score | -40.27 | Piotroski Score | 1 |